Navigation Links
Isis Adds Three New Drugs to Its Development Pipeline
Date:12/14/2011

levels of Lp(a) remain at high risk of cardiovascular events.  There is a significant need for a highly specific drug that can lower Lp(a).   Isis is developing ISIS-APOARx as part of its strategy to create a cardiovascular disease franchise comprised of drugs that target all the key components of cardiovascular disease, including various atherogenic lipids, inflammation and thrombosis.  Isis plans to develop ISIS-APOARx to treat patients with high Lp(a) levels who are at severe risk of experiencing cardiovascular events.

ISIS-DGAT2Rx specifically inhibits diacylglycerol acyltransferase-2, or DGAT-2, a key component in the synthesis of triglycerides.  ISIS-DGAT2Rx is designed to reduce liver fat in patients with nonalcoholic steatohepatitis (NASH), a common and often asymptomatic liver disease that can cause irreversible damage to the liver, and lead to liver cirrhosis and cancer.   The incidence of NASH in the United States is estimated to be more than 20 million, and is expected to increase as the rate of obesity rises.  There are no effective therapies available for patients with NASH and current treatments consist only of lifestyle changes.  In addition, because increase in liver fat is strongly associated with insulin resistance, ISIS-DGAT2Rx could also be beneficial for patients with type 2 diabetes who are insulin resistant.   

ISIS-FVIIRx is designed to reduce Factor VII, a key component of the tissue factor coagulation pathway, for the treatment or prevention of thrombotic diseases without causing bleeding, which is a common side effect of currently available anti-thrombotic drugs.  Elevated levels of Factor VII activity are indicative of poor prognosis in several thrombotic diseases, such as heart attacks.  Furthermore, elevated levels of Factor VII activity are strongly linked to cancer-associated thrombosis, which is the second leading cause of death in cancer pati
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novocure Adds Three Senior Oncology Executives to its Global Management Team
2. RedBrick Health Adds Three Technology Industry Veterans, Launches Health Management Innovation Lab
3. Montage Announces Three More Hospitals Implement Their On-Demand Search and Data Mining Technology for Radiology Studies
4. Thomson Reuters-NPR Health Poll Finds Three in Four Americans Link Narcotic Pain Killers to Drug Addiction
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
6. Three Large Not-for-profit Healthcare Systems Form New Supply Network
7. Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans
8. Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
9. Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
10. Simbionix to Introduce Three New Womens Health Products
11. Poll: One Out of Three U.S. Adults Not Planning to Get Flu Shot This Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
(Date:7/10/2014)... Texas (July 10, 2014) Men who experience hot ... they may find relief from their silent suffering ... according to findings from a Baylor University case study., ... man who had uncontrolled hot flashes following prostate cancer ... flashes but also an impressive improvement in sleep quality, ...
(Date:7/9/2014)... -- The World Health Organization recommends that youth participate ... vigorous physical activity (MVPA) each day. Studies have ... school hours. Therefore, it stands to reason that ... In a new study scheduled for publication in ... time spent outdoors after school was positively associated with ...
(Date:7/9/2014)... July 10, 2014 For the first time, researchers ... Aboriginal population in Canada uses health care. A new ... to clearly demonstrate the unique challenges faced by urban ... St. Michael,s Hospital. , The findings, published today ... urban First Nations individuals and the general population. , ...
(Date:7/9/2014)... of Medicine at the University of Pennsylvania in collaboration ... $8 million grant from the National Cancer Institute (NCI) ... in patients with malignant pleural mesothelioma, a rare, aggressive ... the lining of the lungs and is caused almost ... a clinical trial and additional studies looking at the ...
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
... the current standard of care to treat opioid-dependent ... findings from an international team led by Johns Hopkins ... the New England Journal of Medicine . ... to counter heroin and/or prescription opioid addiction were likely ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Dec. 9 ... on a new trick for weight loss: To eat less ... it up beforehand. Repeatedly imagining the consumption of a ... lead researcher Carey Morewedge, an assistant professor of social and ...
... of Cincinnati (UC) and Massachusetts General Hospital have ... may not be as beneficial to some patients ... findings were published online this week ahead of ... and Outcomes . Warfarin is commonly ...
... A genetic mutation associated with an inherited form of Lou ... lateral sclerosis (ALS) -- has been identified by an international ... are hereditary. In their study, the team used a ... the mutation in the valosin-containing protein (VCP) gene, which has ...
... (HealthDay News) -- Only 50 percent of women over age ... screen for breast cancer, even if they have insurance to ... a database of more than 12 million people to review ... the women included in the study had either employer-provided insurance ...
... of melanoma tumors by targeting the MIC-1 protein that ... better treatment of this invasive and deadly cancer, according ... Foreman Foundation Research Laboratory. , "Preventing vessels from developing ... growing," said lead author Gavin Robertson, Ph.D., professor of ...
Cached Medicine News:Health News:Buprenorphine is better than methadone for opioid dependence in pregnant women, study shows 2Health News:Mental Imagery a New Weight-Loss Tool? 2Health News:Mental Imagery a New Weight-Loss Tool? 3Health News:Blood-thinning treatment standards changing for heart patients, new research shows 2Health News:Blood-thinning treatment standards changing for heart patients, new research shows 3Health News:Only Half of Women Over 40 Get Annual Mammograms 2Health News:Protein targeted to stop melanoma tumor growth 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... This user-friendly instrument ... Plasma Protein analyzer for ... It is a well ... reliable results for a ...
For Detection of Bile Component in Reflux Disease...
Medicine Products: